Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016–2022) from the T1D Exchange Quality Improvement Collaborative
Authors' conclusion
The T1DX-QI cohort showed a significant improvement in HbA1c from 2016 to 2022. Improvements in diabetes device use are also demonstrated. However, these increases were inconsistent across all racial/ethnic groups or insurance types
Study context
- Population
- People living with T1D (PwT1D) from 3 adult and 12 pediatric centers in the T1D Exchange Quality Improvement Collaborative (T1DX-QI), US
- Participants
- >48,000 people
- Exposure
- 2021–2022 vs 2016–2017
- Outcome
- Trends in HbA1c, stratified by race/ethnicity and insurance
- Follow-up
- 2016 to 2022
Methodological detailsmulticenter, national database, 3 adult and 12 pediatric centers
- Multicenter
- National database
- 3 adult and 12 pediatric centers
Main finding
Mean HbA1c
Improvement
0.3 %
P < 0.01
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Increase in % of PwT1D using device · 2016–2017 to 2021–2022
- Continuous glucose monitor (CGM) use increase
- 45%
- Insulin pump use increase
- 12%
- Hybrid closed-loop use increase
- 33%
Inequities, non-Hispanic White vs non-Hispanic Black PwT1D · all 7 years
- Hemoglobin A1c (HbA1c) gap
- 1.2%-1.6%
- CGM gap
- 30%
- Pump gap
- 25%-35%
- Hybrid closed-loop gap
- up to 20%
- Racial/ethnic and insurance-based inequities persisted across all outcomes; improvements not equitable
Original publication
Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016–2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther. Published 16 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →